BOSTON--()--OmniGuide, Inc. a leading developer of advanced microsurgical energy devices announced today that it was ranked in the Deloitte 2012 Technology Fast 500™. The list, which ranks the fastest growing technology companies by percentage revenue growth from 2007-2011, named OmniGuide as one of the fastest growing medical device companies in North America.
“A very large number of women suffer from afflictions like endometriosis and uterine fibroids, which can lead to tremendous pain and infertility. We believe our technology can make a real difference in the surgical treatment of these indications, and a real difference in women’s lives”
“Demonstrating the type of growth that gets recognized in Deloitte’s Technology Fast 500 is outstanding,” said Scott Flora, OmniGuide’s President and CEO. “As a surgical products company, every dollar of revenue growth over this period means another patient treated with our devices. It shows that our work is making a difference in patient care, and that is something of which we are extremely proud.”
"Being recognized as one of the top ten fastest growing medical device companies in North America is a powerful testament to the value that our products deliver to surgeons and patients. It represents an endorsement of OmniGuide's technology, its products, and the dedicated team of people focused on delivering superior surgical tools that improve patient outcomes,” added Yoel Fink, OmniGuide's founder, Chairman, and former CEO.
OmniGuide’s novel devices include its BeamPath® product line, a proprietary flexible CO2 laser system that enables an extremely precise, bloodless cut and prevents damage to the surrounding tissue. The products are used in thousands of procedures annually in the United States across Ear, Nose, & Throat (ENT), Neurosurgery, and now in Women’s Health.
“A very large number of women suffer from afflictions like endometriosis and uterine fibroids, which can lead to tremendous pain and infertility. We believe our technology can make a real difference in the surgical treatment of these indications, and a real difference in women’s lives,” added Mr. Flora. “With our 2012 product launches into minimally invasive gynecology – both traditional laparoscopy and robotic assisted surgery – we believe we can continue on the progress we have made since 2007.”
About Deloitte’s 2012 Technology Fast 500™
The Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private in the U.S. and Canada. Technology Fast 500 award winners for 2012 are selected based on percentage fiscal year revenue growth during the period from 2007 to 2011.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year (2007) operating revenues of at least $50,000 USD or CD, and current-year (2011) operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.
OmniGuide, Inc. is a leader in the development and marketing of precision surgical energy solutions that improve patients’ lives. By leveraging its proprietary flexible CO2 laser technology, OmniGuide products enhance surgical accuracy, access, and control for microsurgical applications, laparoscopy, and robotically assisted surgery. Sold under the BeamPath® brand in the United States through a direct sales force and through distribution partners in Europe, the company is committed to shaping the future of minimally invasive surgery.
For more information please visit www.omni-guide.com